Improvement of predictive models of risk of disease progression in chronic hepatitis C by incorporating longitudinal data

Hepatology

Volumn 61, Issue 6, 2015, Pages 1832-1841

  Konerman, Monica A ^a   Zhang, Yiwei ^a   Zhu, Ji ^a   Higgins, Peter D R ^a   Lok, Anna S F ^a   Waljee, Akbar K ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON;

ADULT; ARTICLE; CHILD TURCOTTE PUGH SCORE; CHRONIC HEPATITIS C; CLINICAL PRACTICE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER GRAFT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOM FOREST; RISK FACTOR; SENSITIVITY AND SPECIFICITY; ARTIFICIAL INTELLIGENCE; BIOLOGICAL MODEL; CLINICAL TRIAL; FIBROSIS; LIVER; PATHOLOGY; RISK ASSESSMENT; STATISTICS;

ARTIFICIAL INTELLIGENCE; DISEASE PROGRESSION; FEMALE; FIBROSIS; HEPATITIS C, CHRONIC; HUMANS; LIVER; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RISK ASSESSMENT; STATISTICS AS TOPIC;

EID: 84929606990     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27750     Document Type: Article

References (25)

1. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-1887.
2. Olysio (simeprevir): Full prescribing information. Titusville, NJ: Janssen Therapeutics; 2013.
3. Colvin HM, Mitchell AE, eds.; Committee on the Prevention and Control of Viral Hepatitis Infections, Institute of Medicine. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: National Academies Press; 2010.
4. Moyer VA. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013;159:349-357.
5. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012;61:1-32.
6. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17:107-115.
7. Konerman MA, Yapali S, Lok AS. Systematic Review: Identifying patients in need of early treatment and intensive monitoring-predictors and predictive models of disease progression in chronic hepatitis C. Aliment Pharmacol Ther 2014;40:863-879.
8. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004;25:472-492.
9. Tibshirani R. Regression shrinkage and selection via the lasso. J R Statist Soc 1996;58:267-288.
10. Friedman J HT, Tibshirani R. Additive logistic regression: a statistical view of boosting. Ann Stat 1998;28:2000.
11. Liaw A, Wiener M. Classification and regression by random forest. R News 2002;2:18-22.
12. Schapire RE. The boosting approach to machine learning: an overview. In Denison DD, ed. Nonlinear Estimation and Classification. Lecture Notes in Statistics, vol. 171. New York: Springer Science+Business Media; 2003:149-171.
13. Waljee AK, Mukherjee A, Singal AG, Zhang Y, Warren J, Balis U, et al. Comparison of imputation methods for missing laboratory data in medicine. BMJ Open 2013;3.
14. Brieiman L. Random forests. Machine Learning 2001;45:5-32.
15. U.S. Food and Drug Administration approves Gilead's Sovaldi (sofosbuvir) for the treatment of chronic hepatitis C [press release]. Foster City, CA: Gilead; December 6, 2013. Available at: http://www.gilead.com/news/press-releases/2013/12/us-food-and-drug-administration-approves-gileads-sovaldi-sofosbuvir-for-the-treatment-of-chronic-hepatitis-c.
16. Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, et al. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut 2010;59:1401-1409.
17. Baran B, Gulluoglu M, Soyer OM, Ormeci AC, Gokturk S, Evirgen S, et al. Treatment failure may lead to accelerated fibrosis progression in patients with chronic hepatitis C. J Viral Hepat 2014;21:111-120.
18. Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003;124:97-104.
19. Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Komatsu N, et al. The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy. J Hepatol 2008;48:736-742.
20. Mummadi RR, Petersen JR, Xiao SY, Snyder N. Role of simple biomarkers in predicting fibrosis progression in HCV infection. World J Gastroenterol 2010;16:5710-5715.
21. Williams MJ, Lang-Lenton M. Progression of initially mild hepatic fibrosis in patients with chronic hepatitis C infection. J Viral Hepat 2011;18:17-22.
22. Kwon H, Lok AS. Does antiviral therapy prevent hepatocellular carcinoma? Antivir Ther 2011;16:787-795.
23. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, et al. Maintenence peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2011;140:840-849.
24. Waljee AK, Higgins PD. Machine learning in medicine: a primer for physicians. Am J Gastroenterol 2010;105:1224-1226.
25. Waljee AK, Joyce JC, Wang S, Saxena A, Hart M, Zhu J, et al. Algorithms outperform metabolite tests in predicting response of patients with inflammatory bowel disease to thiopurines. Clin Gastroenterol Hepatol 2010;8:143-150.